// App-Quantinova.ai

: Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database

Researchers

Presenter

  • Lea Hoisnard

Principal Investigators

  • Bénédicte Lebrun-Vignes

  • Sébastien Maury

  • Matthieu Mahévas

  • Khalil El Karoui

  • Dr Lydia Roy

  • José L Cohen

  • Aurélien Amiot

  • Pascal Claudepierre

  • Philippe Grimbert

  • Emilie Sbidian

Medical Centers

  • The University of Chicago, Pritzker School of Medicine

  • Dept. of Pediatrics, Section of Dermatology

  • Dept. of Pediatrics, Section of Dermatology

Locations

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Infectious Diseases (ID)

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

  • Influenza

Biomarkers

  • Janus kinase

Drug/Treatment

  • Baricitinib

  • Tasocitinib

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved